Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants

Launched by GERMANS TRIAS I PUJOL HOSPITAL · Mar 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how certain immune responses in patients with major depression might affect their symptoms and how well they respond to a common type of antidepressant called selective serotonin reuptake inhibitors (SSRIs). The researchers want to understand if there are specific markers of inflammation in the body that relate to feelings of anxiety, depression, irritability, fatigue, and cognitive issues. They will study 30 patients with major depression who are starting treatment with SSRIs, comparing their results over three months to a control group of 20 healthy individuals.

To participate in this study, individuals must be between 18 and 65 years old and diagnosed with major depression by a psychiatrist. They should not have received any antidepressant or antipsychotic medications in the six weeks before joining, and they should not have any serious medical conditions or substance use issues. Participants can expect to undergo evaluations at the start of the study and again after three months, which will include assessments of their mental health symptoms and some blood tests to check their immune response. This study aims to help improve treatment strategies for depression by better understanding the relationship between inflammation and mood symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 65 years
• • Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5).
• • Eligible for receiving antidepressant treatment for major depression.
• Exclusion Criteria:
• • Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study.
• • Who present concurrent psychotic symptoms.
• • Who present disorders due to alcohol or drug use, with active consumption during the last 3 months.
• • Pregnant women.
• • Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies.